HIV drug switch may protect hearts: small study tests doravirine
NCT ID NCT04820933
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 40 times
Summary
This completed early-phase trial tested whether switching HIV medications to doravirine (with emtricitabine and tenofovir alafenamide) could improve cholesterol and reduce early signs of artery hardening compared to staying on integrase inhibitors. Twenty-six adults with well-controlled HIV and high cholesterol took part. The study measured blood markers linked to heart disease risk, not actual heart events.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR RISK FACTOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas Southwestern
Dallas, Texas, 75219, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75219, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Doravirine 100 mg (with emtricitabine and tenofovir alafenamide)
What this could lead to
If successful, this could show that doravirine is a better option for people with HIV to lower their risk of heart disease and improve cholesterol levels.
What could go wrong
This is a very small, early-phase study with only 26 participants, so results may not apply to everyone. It looked at lab markers, not actual heart attacks, so real-world benefits are uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.